Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ellsworth

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Bioorganic & Medicinal Chemistry|February 23, 2024
Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug designChunjian Liu, Wei Wang, Jianxin Feng, et al.
NPJ Genomic Medicine|April 9, 2022
Best practices for the interpretation and reporting of clinical whole genome sequencingChristina A Austin-Tse, Vaidehi Jobanputra, Denise L Perry, et al.
Human Mutation|January 13, 2022
Expanding the phenotypic and molecular spectrum of NFS1-related disorders that cause functional deficiencies in mitochondrial and cytosolic iron-sulfur cluster containing enzymesJennifer H Yang, Marisa W Friederich, Katarzyna A Ellsworth, et al.
Journal of Medicinal Chemistry|August 15, 2022
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3Chunjian Liu, Prasada Rao Jalagam, Jianxin Feng, et al.
Journal of Medicinal Chemistry|June 15, 2022
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic SteatohepatitisSusheel J Nara, Srinivas Jogi, Srinivas Cheruku, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2021
Phylogenetically diverse diets favor more complex venoms in North American pitvipersMatthew L Holding, Jason L Strickland, Rhett M Rautsaw, et al.
Journal of Medicinal Chemistry|February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesWei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Journal of Medicinal Chemistry|November 5, 2013
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic propertiesBruce A Ellsworth, Philip M Sher, Ximao Wu, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
American Journal of Medical Genetics. Part A|July 26, 2020
Genotype-phenotype correlation at codon 1740 of SETD2Rachel Rabin, Alireza Radmanesh, Ian A Glass, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Bioorganic & Medicinal Chemistry|February 23, 2024
Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug designChunjian Liu, Wei Wang, Jianxin Feng, et al.
NPJ Genomic Medicine|April 9, 2022
Best practices for the interpretation and reporting of clinical whole genome sequencingChristina A Austin-Tse, Vaidehi Jobanputra, Denise L Perry, et al.
Human Mutation|January 13, 2022
Expanding the phenotypic and molecular spectrum of NFS1-related disorders that cause functional deficiencies in mitochondrial and cytosolic iron-sulfur cluster containing enzymesJennifer H Yang, Marisa W Friederich, Katarzyna A Ellsworth, et al.
Journal of Medicinal Chemistry|August 15, 2022
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3Chunjian Liu, Prasada Rao Jalagam, Jianxin Feng, et al.
Journal of Medicinal Chemistry|June 15, 2022
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic SteatohepatitisSusheel J Nara, Srinivas Jogi, Srinivas Cheruku, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2021
Phylogenetically diverse diets favor more complex venoms in North American pitvipersMatthew L Holding, Jason L Strickland, Rhett M Rautsaw, et al.
Journal of Medicinal Chemistry|February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesWei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Journal of Medicinal Chemistry|November 5, 2013
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic propertiesBruce A Ellsworth, Philip M Sher, Ximao Wu, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
American Journal of Medical Genetics. Part A|July 26, 2020
Genotype-phenotype correlation at codon 1740 of SETD2Rachel Rabin, Alireza Radmanesh, Ian A Glass, et al.
Pageof 18